CBIO CRESCENT BIOPHARMA INC.

Crescent Biopharma to Present at November Investor Conferences

Crescent Biopharma to Present at November Investor Conferences

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in November:

  • Guggenheim 2nd Annual Healthcare Innovation Conference, fireside chat on Tuesday, November 11, 2025, at 8:00 a.m. ET in Boston.

  • Stifel 2025 Healthcare Conference, fireside chat on Wednesday, November 12, 2025, at 1:20 p.m. ET in New York.

  • Jefferies Global Healthcare Conference, fireside chat on Wednesday, November 19, 2025, at 9:30 a.m. GMT (4:30 a.m. ET) in London.

A live webcast of each presentation will be available in the Investors section of Crescent's website at , and a replay will be accessible for 90 days.

About Crescent Biopharma

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit  and follow the Company on and .

Contact:

Amy Reilly

Chief Communications Officer



617-465-0586



EN
05/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CRESCENT BIOPHARMA INC.

 PRESS RELEASE

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Re...

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights IND Submission for CR-001, a PD-1 x VEGF Bispecific Antibody, on Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors  Advancing ADCs in the Pipeline, with IND Submission for CR-002 on Track for Mid-2026 WALTHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- . (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial results for...

 PRESS RELEASE

Crescent Biopharma to Present at November Investor Conferences

Crescent Biopharma to Present at November Investor Conferences WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation Conference, fireside chat on Tuesday, November 11, 2025, at 8:00 a.m. ET in Boston.Stifel 2025 Healthcare Conference, fireside chat on Wednesday, November 12, 2025, at 1:20 p...

 PRESS RELEASE

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VE...

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting CR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity IND Submission for CR-001 On Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today an...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch